Instil Bio, Inc. (TIL) stock
TILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.24−0.07 (-1.11%)
Close on Nov 12, 2026Market cap $42.32MP/E –Yield –
Instil Bio r&d expenses
Research and development expenses are spending on new products and technology.
Instil Bio's R&D Expenses for the twelve months ending Jun 30, 2026 was $13.56M, down 1.5% year over year. For fiscal 2025 it was $24.74M, up 109.0% from the year before. The highest annual figure on record is $141.06M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.74M | +109.0% |
| FY2024 | Dec 31, 2024 | $11.84M | -70.1% |
| FY2023 | Dec 31, 2023 | $39.60M | -71.9% |
| FY2022 | Dec 31, 2022 | $141.06M | +31.5% |
| FY2021 | Dec 31, 2021 | $107.25M | +452.9% |
| FY2020 | Dec 31, 2020 | $19.40M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $270.00K | -96.0% |
| Q1 FY2026 | Mar 31, 2026 | $669.00K | -87.5% |
| Q4 FY2025 | Dec 31, 2025 | $3.50M | +218.2% |
| Q3 FY2025 | Sep 30, 2025 | $9.13M | +1524.0% |
| Q2 FY2025 | Jun 30, 2025 | $6.74M | +130.8% |
| Q1 FY2025 | Mar 31, 2025 | $5.37M | -26.0% |
| Q4 FY2024 | Dec 31, 2024 | $1.10M | -44.6% |
| Q3 FY2024 | Sep 30, 2024 | $562.00K | -93.4% |
| Q2 FY2024 | Jun 30, 2024 | $2.92M | -65.5% |
| Q1 FY2024 | Mar 31, 2024 | $7.26M | -64.9% |
| Q4 FY2023 | Dec 31, 2023 | $1.98M | -90.4% |
| Q3 FY2023 | Sep 30, 2023 | $8.49M | -78.6% |
| Q2 FY2023 | Jun 30, 2023 | $8.46M | -79.6% |
| Q1 FY2023 | Mar 31, 2023 | $20.67M | -47.2% |
| Q4 FY2022 | Dec 31, 2022 | $20.72M | -51.3% |
| Q3 FY2022 | Sep 30, 2022 | $39.66M | +36.5% |
| Q2 FY2022 | Jun 30, 2022 | $41.50M | +95.9% |
| Q1 FY2022 | Mar 31, 2022 | $39.17M | +171.6% |
| Q4 FY2021 | Dec 31, 2021 | $42.58M | +315.5% |
| Q3 FY2021 | Sep 30, 2021 | $29.06M | +492.2% |
| Q2 FY2021 | Jun 30, 2021 | $21.19M | +847.1% |
| Q1 FY2021 | Mar 31, 2021 | $14.42M | +618.7% |
| Q4 FY2020 | Dec 31, 2020 | $10.25M | – |
| Q3 FY2020 | Sep 30, 2020 | $4.91M | – |
| Q2 FY2020 | Jun 30, 2020 | $2.24M | – |
| Q1 FY2020 | Mar 31, 2020 | $2.01M | – |
See a number that looks wrong?